Skin AgeingPhase 2NCT07359924

PRF in Face Care Cream.

A Phase 2 study testing The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20, The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with additional growth factor EGF and The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with autologus PRF in people with Skin Ageing, run by Poznan University of Medical Sciences at 1 site in Poland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 20 to 40 years, women onlyHealthy volunteers can take part
Conditions the study is for: Skin Ageing
What is being tested?: The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20, The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with additional growth factor EGF and The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with autologus PRF
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 20 participants
Where: 1 sitePoland
Study dates: 3 Feb 2022to 6 Feb 2023
Phase: Phase 2
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 20 to 40 years
Women only
Healthy volunteers accepted
Adult

Who may be able to join

healthy volunteers with healthy skin, who sign an agreement for study participation

Who cannot join

systemic diseases, smoking, blood disorders, acute viral infections and skin inflammations, pregnancy, and breastfeeding.

Trial locations and contacts

1 site in 1 country.

Poland1 site

Poznan University of Medical Sciences
Poznan, The Greater Poland, 60-812

Other trials in Poland

About this study

Official title: Application of Liquid Fraction of Platelet-rich Fibrin in Face Care Cream.

The study evaluates the effectiveness of cosmetic preparations containing PRF, conducted through in vivo studies. Material and Methods: The study involved 20 healthy volunteers (aged 20-40) who received three identically packaged creams to be applied to specific facial areas. Formulation 1: base formulation (control), Formulation 2: base formulation with human epidermal growth factor (EGF), and Formulation 3: base formulation with platelet-rich fibrin (PRF). Volunteers applied the creams as directed for a period of four weeks. Skin assessments was conducted at baseline (week 0), and at weeks 1, 2, and 4. Trans-epidermal Water Loss (TEWL), skin hydration using corneometry to determine the moisture content of the stratum corneum, skin elasticity using a cutometer to measure the skin's ability to return to its original state after deformation, and dermal bioavailability were measured. EGF concentration in the stratum corneum will be measured using the tape-stripping method followed by HPLC (High-Performance Liquid Chroma-tography) analysis. Results: A significant decrease in TEWL was observed in formulations 2 and 3, indicating improved skin barrier function. Formulation 3 showed the highest increase in skin hy-dration, followed by formulation 2. Both formulations 2 and 3 demonstrated improvements in skin elasticity, with formulation 3 showing the greatest enhancement. EGF concentration in the stratum corneum increased over the four-week period, reaching equilibrium with the product concentration by week four. Con-clusion: The in vivo instrumental compatibility studies confirmed that the new cosmetic formulations containing EGF and PRF are safe and effective for human skin.

Conditions: Skin Ageing
Being tested: The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20, The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with additional growth factor EGF, The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with autologus PRF
Keywords: PRF, skin, cream, EGF

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20Combination product
Daily skin application for the following 4 weeks at the same place according to the instruction
The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with additional growth factor EGFCombination product
Daily skin application for the following 4 weeks at the same place according to the instruction
The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with autologus PRFBiological
Daily skin application for the following 4 weeks at the same place according to the instruction

Study groups in NCT07359924
Study group	Role	What they receive
Formulation 1	Placebo comparator	Base formulation Receives: Combination Product: The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20
Formulation 2	Active comparator	Formulation with growth factor EGF Receives: Combination Product: The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with additional growth factor EGF
Formulation 3	Experimental	Formulation with PRF Receives: Biological: The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with autologus PRF

What is being measured

The primary outcome is the main question the study is designed to answer.

Skin water content
To measure the hydration of skin, an apparatus called a corneometer is used (Corneometer® CM 825 (Courage+Khazaka electronic GmbH)). It allows an accurate, reproducible and objective measurement of the hydration level of the stratum corneum of the skin. It records changes in electrical capacitance, consistent with the water content of the skin.
Measured: Baseline
Transepidermal water loss
Tewameter
Measured: Baseline
Skin topography
Visioscan® VC98 and Visioline® VL650
Measured: Baseline
Skin elasticity
Cutometer
Measured: Baseline
Dermal Bioavailability
Tape-Stripping Method
Measured: Baseline
Skin water content
To measure the hydration of skin, an apparatus called a corneometer is used (Corneometer® CM 825 (Courage+Khazaka electronic GmbH)). It allows an accurate, reproducible and objective measurement of the hydration level of the stratum corneum of the skin. It records changes in electrical capacitance, consistent with the water content of the skin.
Measured: After 1 week
Skin water content
To measure the hydration of skin, an apparatus called a corneometer is used (Corneometer® CM 825 (Courage+Khazaka electronic GmbH)). It allows an accurate, reproducible and objective measurement of the hydration level of the stratum corneum of the skin. It records changes in electrical capacitance, consistent with the water content of the skin.
Measured: After 2 weeks
Skin water content
To measure the hydration of skin, an apparatus called a corneometer is used (Corneometer® CM 825 (Courage+Khazaka electronic GmbH)). It allows an accurate, reproducible and objective measurement of the hydration level of the stratum corneum of the skin. It records changes in electrical capacitance, consistent with the water content of the skin.
Measured: After 4 weeks
Transepidermal water loss
Tewameter
Measured: After 1 week
Transepidermal water loss
Tewameter
Measured: After 2 weeks
Transepidermal water loss
Tewameter
Measured: After 4 weeks
Skin topography
Visioscan® VC98 and Visioline® VL650
Measured: After 4 weeks
Skin elasticity
Cutometer
Measured: After 4 weeks
Dermal Bioavailability
Tape-Stripping Method
Measured: After 4 weeks

Secondary outcomes (11)

Stability Evaluation of cream formulations
The stability tests of the formulations were carried out immediately after preparation and after 60 days of storage at 40°C. From the obtained results, the arithmetic mean, and standard deviation were calculated. Each sample was tested three times, and the arithmetic mean, and standard deviation were computed from the results.
Measured: Baseline
Stability Evaluation of cream formulations
The stability tests of the formulations were carried out immediately after preparation and after 60 days of storage at 40°C. From the obtained results, the arithmetic mean, and standard deviation were calculated. Each sample was tested three times, and the arithmetic mean, and standard deviation were computed from the results.
Measured: After 60 days
pH Measurement of cream formulations
The pH of the cosmetic emulsions was measured three times using the EcoSense® pH 10 pH/Temperature Meter, Pen Style (VMR International).
Measured: Baseline
pH Measurement of cream formulations
The pH of the cosmetic emulsions was measured three times using the EcoSense® pH 10 pH/Temperature Meter, Pen Style (VMR International).
Measured: After 12 weeks
Cream Viscosity Measurement
The viscosity of the cosmetic emulsions was measured three times using the RC02 rotational viscometer (Rheotec).
Measured: Baseline
Light Scattering Stability Analysis
Stability analysis of the formulations was performed using the multiple light scattering method with the Turbiscan Lab Expert device (Formulaction SA).
Measured: Baseline
Growth Factor Quantification in Cosmetic Formulations
The quantification of the growth factor in the obtained cosmetic formulations was conducted using a high-performance liquid chromatograph (HPLC) Varian 920-LC (Agilent Technologies), equipped with an automatic injector and sample feeder. Both qualitative and quantitative methodologies were developed for the analysis of the cosmetic preparations.
Measured: Baseline
Stability Testing Points
Stability tests for all formulations included four measurement points, analyzing the samples after 2, 4, 8, and 12 weeks of storage in climate chambers. The comprehensive testing ensured that the formulations maintained their desired properties and remained safe and effective for use throughout the study.
Measured: After 2 weeks
Stability Testing Points
Stability tests for all formulations included four measurement points, analyzing the samples after 2, 4, 8, and 12 weeks of storage in climate chambers. The comprehensive testing ensured that the formulations maintained their desired properties and remained safe and effective for use throughout the study.
Measured: After 4 weeks
Stability Testing Points
Stability tests for all formulations included four measurement points, analyzing the samples after 2, 4, 8, and 12 weeks of storage in climate chambers. The comprehensive testing ensured that the formulations maintained their desired properties and remained safe and effective for use throughout the study.
Measured: After 8 weeks
Stability Testing Points
Stability tests for all formulations included four measurement points, analyzing the samples after 2, 4, 8, and 12 weeks of storage in climate chambers. The comprehensive testing ensured that the formulations maintained their desired properties and remained safe and effective for use throughout the study.
Measured: After 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

3 Feb 20226 Feb 2023

First posted22 Jan 2026
Study start3 Feb 2022
Primary completion8 Aug 2022
Study completion6 Feb 2023

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (8)Papers the sponsor has linked to this study.
Other trials for Skin AgeingStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Prevention
Allocation: Non-randomised
Intervention model: Factorial
Model description: Patients received three uniformly appearing creams with instruc-tions for application on specific facial areas every morning and evening. Skin reassessment was conducted after 1, 2, and 4 weeks from the start of application. During the four weeks of the study, baseline measurements (elasticity, hydration and transepidermal water loss) were taken weekly, with skin topography and mac-rosculpture additionally examined in weeks 0 and 4.
Masking: Single blind
Who is masked: Participant
Enrolment: 20 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07359924
Sponsor's protocol ID: PUMS-308/18
Status last verified: Jan 2026
First submitted: 13 Jan 2026
Last updated: 22 Jan 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Publications

Trojahn C, Dobos G, Schario M, Ludriksone L, Blume-Peytavi U, Kottner J. Relation between skin micro-topography, roughness, and skin age. Skin Res Technol. 2015 Feb;21(1):69-75. doi: 10.1111/srt.12158. Epub 2014 Jun 3.
PubMed 24889351
Dabrowska M, Mielcarek A, Nowak I. Evaluation of sex-related changes in skin topography and structure using innovative skin testing equipment. Skin Res Technol. 2018 Nov;24(4):614-620. doi: 10.1111/srt.12473. Epub 2018 Apr 29.
PubMed 29707820
12. Zalewska A., Kowalik J., Grubecki I., Application of turbiscan lab to study the effect of emulsifier content on the stability of plant origin dispersion. Chem. Process Eng. 2019; 40(4): 399-409
Gardien KL, Baas DC, de Vet HC, Middelkoop E. Transepidermal water loss measured with the Tewameter TM300 in burn scars. Burns. 2016 Nov;42(7):1455-1462. doi: 10.1016/j.burns.2016.04.018. Epub 2016 May 24.
PubMed 27233677
Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. 2009 Feb;27(1):63-9. doi: 10.1080/08977190802636713.
PubMed 19089687
Arshdeep; Kumaran MS. Platelet-rich plasma in dermatology: boon or a bane? Indian J Dermatol Venereol Leprol. 2014 Jan-Feb;80(1):5-14. doi: 10.4103/0378-6323.125467.
PubMed 24448117
Dohan Ehrenfest DM, Bielecki T, Mishra A, Borzini P, Inchingolo F, Sammartino G, Rasmusson L, Everts PA. In search of a consensus terminology in the field of platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol. 2012 Jun;13(7):1131-7. doi: 10.2174/138920112800624328.
PubMed 21740379
Feingold KR, Denda M. Regulation of permeability barrier homeostasis. Clin Dermatol. 2012 May-Jun;30(3):263-8. doi: 10.1016/j.clindermatol.2011.08.008.
PubMed 22507038

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
Ultraformer MPT Combined With Fractional CO2 Versus Fractional CO2 Alone for Facial Rejuvenation
Skin Aging
Enrolling by invitationEarly Phase 1
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
Aging
Not yet recruiting
Effects of Probiotics on Skin Health in Healthy Women
Skin Aging, Dry Skin
Not yet recruiting
Evaluation of MD60002 Device for Facial Skin Aging
Facial Wrinkles, Skin Aging
RecruitingPhase 3
Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness
Skin Quality

All Skin Ageing trials

Study at a glance

From the registry record, last updated by the sponsor on 22 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Application of Liquid Fraction of Platelet-rich Fibrin in Face Care Cream.
ClinicalTrials.gov ID: NCT07359924
Acronym / sponsor ID: PUMS-308/18
Conditions: Skin Ageing
Keywords: PRF, skin, cream, EGF
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 20 participants (actual)
Lead sponsor: Poznan University of Medical SciencesUniversity, hospital or other
Study start: 3 Feb 2022 (actual)
Primary completion: 8 Aug 2022 (actual)
Study completion: 6 Feb 2023 (actual)
First posted: 22 Jan 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Prevention
Allocation: Non-randomised
Intervention model: Factorial
Masking: Single blind (participant)
Number of arms: 3
Model description: Patients received three uniformly appearing creams with instruc-tions for application on specific facial areas every morning and evening. Skin reassessment was conducted after 1, 2, and 4 weeks from the start of application. During the four weeks of the study, baseline measurements (elasticity, hydration and transepidermal water loss) were taken weekly, with skin topography and mac-rosculpture additionally examined in weeks 0 and 4.

Arm	Type	Receives
Formulation 1	Placebo comparator	Combination Product: The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20Base formulation
Formulation 2	Active comparator	Combination Product: The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with additional growth factor EGFFormulation with growth factor EGF
Formulation 3	Experimental	Biological: The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with autologus PRFFormulation with PRF

Who may qualify

Ages: 20 to 40 years
Sex: Female only
Healthy volunteers: Accepted
Age groups: Adult

Key inclusion criteria (1 listed)

healthy volunteers with healthy skin, who sign an agreement for study participation

Key exclusion criteria (1 listed)

systemic diseases, smoking, blood disorders, acute viral infections and skin inflammations, pregnancy, and breastfeeding.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20Daily skin application for the following 4 weeks at the same place according to the instruction	Combination product	Formulation 1
The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with additional growth factor EGFDaily skin application for the following 4 weeks at the same place according to the instruction	Combination product	Formulation 2
The cream base formulation containing oil phase, Creagel EZ® 7 and Alphaflow® 20 with autologus PRFDaily skin application for the following 4 weeks at the same place according to the instruction	Biological	Formulation 3

Primary outcome

Skin water content
Time frame: Baseline
To measure the hydration of skin, an apparatus called a corneometer is used (Corneometer® CM 825 (Courage+Khazaka electronic GmbH)). It allows an accurate, reproducible and objective measurement of the hydration level of the stratum corneum of the skin. It records changes in electrical capacitance, consistent with the water content of the skin.
Transepidermal water loss
Time frame: Baseline
Tewameter
Skin topography
Time frame: Baseline
Visioscan® VC98 and Visioline® VL650
Skin elasticity
Time frame: Baseline
Cutometer
Dermal Bioavailability
Time frame: Baseline
Tape-Stripping Method
Skin water content
Time frame: After 1 week
To measure the hydration of skin, an apparatus called a corneometer is used (Corneometer® CM 825 (Courage+Khazaka electronic GmbH)). It allows an accurate, reproducible and objective measurement of the hydration level of the stratum corneum of the skin. It records changes in electrical capacitance, consistent with the water content of the skin.
Skin water content
Time frame: After 2 weeks
To measure the hydration of skin, an apparatus called a corneometer is used (Corneometer® CM 825 (Courage+Khazaka electronic GmbH)). It allows an accurate, reproducible and objective measurement of the hydration level of the stratum corneum of the skin. It records changes in electrical capacitance, consistent with the water content of the skin.
Skin water content
Time frame: After 4 weeks
To measure the hydration of skin, an apparatus called a corneometer is used (Corneometer® CM 825 (Courage+Khazaka electronic GmbH)). It allows an accurate, reproducible and objective measurement of the hydration level of the stratum corneum of the skin. It records changes in electrical capacitance, consistent with the water content of the skin.
Transepidermal water loss
Time frame: After 1 week
Tewameter
Transepidermal water loss
Time frame: After 2 weeks
Tewameter
Transepidermal water loss
Time frame: After 4 weeks
Tewameter
Skin topography
Time frame: After 4 weeks
Visioscan® VC98 and Visioline® VL650
Skin elasticity
Time frame: After 4 weeks
Cutometer
Dermal Bioavailability
Time frame: After 4 weeks
Tape-Stripping Method

11 secondary outcomes

Stability Evaluation of cream formulations
Time frame: Baseline
Stability Evaluation of cream formulations
Time frame: After 60 days
pH Measurement of cream formulations
Time frame: Baseline
pH Measurement of cream formulations
Time frame: After 12 weeks
Cream Viscosity Measurement
Time frame: Baseline
Light Scattering Stability Analysis
Time frame: Baseline
Growth Factor Quantification in Cosmetic Formulations
Time frame: Baseline
Stability Testing Points
Time frame: After 2 weeks
Stability Testing Points
Time frame: After 4 weeks
Stability Testing Points
Time frame: After 8 weeks
Stability Testing Points
Time frame: After 12 weeks

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2026.
Results publication: PubMed 24889351Trojahn C, Dobos G, Schario M, Ludriksone L, Blume-Peytavi U, Kottner J. Relation between skin micro-topography, roughness, and skin age. Skin Res Technol. 2015 Feb;21(1):69-75. doi: 10.1111/srt.12158. Epub 2014 Jun 3.
Results publication: PubMed 29707820Dabrowska M, Mielcarek A, Nowak I. Evaluation of sex-related changes in skin topography and structure using innovative skin testing equipment. Skin Res Technol. 2018 Nov;24(4):614-620. doi: 10.1111/srt.12473. Epub 2018 Apr 29.
Results publication12. Zalewska A., Kowalik J., Grubecki I., Application of turbiscan lab to study the effect of emulsifier content on the stability of plant origin dispersion. Chem. Process Eng. 2019; 40(4): 399-409
Results publication: PubMed 27233677Gardien KL, Baas DC, de Vet HC, Middelkoop E. Transepidermal water loss measured with the Tewameter TM300 in burn scars. Burns. 2016 Nov;42(7):1455-1462. doi: 10.1016/j.burns.2016.04.018. Epub 2016 May 24.
Results publication: PubMed 19089687Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. 2009 Feb;27(1):63-9. doi: 10.1080/08977190802636713.
Results publication: PubMed 24448117Arshdeep; Kumaran MS. Platelet-rich plasma in dermatology: boon or a bane? Indian J Dermatol Venereol Leprol. 2014 Jan-Feb;80(1):5-14. doi: 10.4103/0378-6323.125467.
Results publication: PubMed 21740379Dohan Ehrenfest DM, Bielecki T, Mishra A, Borzini P, Inchingolo F, Sammartino G, Rasmusson L, Everts PA. In search of a consensus terminology in the field of platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol. 2012 Jun;13(7):1131-7. doi: 10.2174/138920112800624328.
Results publication: PubMed 22507038Feingold KR, Denda M. Regulation of permeability barrier homeostasis. Clin Dermatol. 2012 May-Jun;30(3):263-8. doi: 10.1016/j.clindermatol.2011.08.008.
Individual participant dataSharing planned: Yes. The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Related trials for Skin Ageing

Recruiting
Ultraformer MPT Combined With Fractional CO2 Versus Fractional CO2 Alone for Facial Rejuvenation
Skin Aging
Enrolling by invitationEarly Phase 1
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
Aging
Not yet recruiting
Effects of Probiotics on Skin Health in Healthy Women
Skin Aging, Dry Skin
Not yet recruiting
Evaluation of MD60002 Device for Facial Skin Aging
Facial Wrinkles, Skin Aging
RecruitingPhase 3
Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness
Skin Quality

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Marzena Liliana Wyganowska, Prof. study chair

Departament of Periodontology and Oral Mucosa Diseases PUMS

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Skin water content (time frame: Baseline). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07359924, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2026.